Brian Higgins

5.9k total citations · 3 hit papers
38 papers, 2.9k citations indexed

About

Brian Higgins is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Brian Higgins has authored 38 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 25 papers in Molecular Biology and 5 papers in Infectious Diseases. Recurrent topics in Brian Higgins's work include Cancer-related Molecular Pathways (17 papers), Melanoma and MAPK Pathways (7 papers) and Angiogenesis and VEGF in Cancer (6 papers). Brian Higgins is often cited by papers focused on Cancer-related Molecular Pathways (17 papers), Melanoma and MAPK Pathways (7 papers) and Angiogenesis and VEGF in Cancer (6 papers). Brian Higgins collaborates with scholars based in United States, Switzerland and Canada. Brian Higgins's co-authors include Kathryn Packman, Kenneth Kolinsky, David Heimbrook, Christian Tovar, Zoran Filipovic, Weiguo Qing, James Rosinski, Lyubomir T. Vassilev, Ola Myklebost and Xiaolan Zhao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Brian Higgins

38 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

2006 553 citations Christian Tovar, James Rosinski et al. Proceedings of the National Academy of Sciences profile →
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

2013 447 citations Qingjie Ding, Zhuming Zhang et al. Journal of Medicinal Chemistry profile →
MDM2 inhibition: an important step forward in cancer therapy

2020 276 citations Marina Konopleva, Giovanni Martinelli et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Higgins United States	23	2.0k	1.7k	453	403	272	38	2.9k
Kathryn Packman United States	28	2.6k 1.3×	2.2k 1.3×	481 1.1×	484 1.2×	343 1.3×	65	3.9k
Christian Tovar United States	18	2.3k 1.2×	1.9k 1.1×	304 0.7×	356 0.9×	353 1.3×	26	3.2k
Kenneth Kolinsky United States	19	1.3k 0.7×	1.3k 0.8×	350 0.8×	294 0.7×	164 0.6×	33	2.3k
Emily A. Liu United States	5	2.9k 1.5×	2.3k 1.4×	225 0.5×	489 1.2×	448 1.6×	5	3.9k
Robert J. Kinders United States	36	2.3k 1.2×	1.9k 1.1×	484 1.1×	812 2.0×	144 0.5×	129	4.0k
Terence O’Reilly Switzerland	24	2.0k 1.0×	1.1k 0.7×	668 1.5×	421 1.0×	163 0.6×	36	3.2k
Enrico Pesenti Italy	28	1.3k 0.7×	1.0k 0.6×	371 0.8×	362 0.9×	227 0.8×	67	2.7k
Paula M. Fracasso United States	31	1.0k 0.5×	1.6k 1.0×	477 1.1×	380 0.9×	153 0.6×	109	3.0k
Lyubomir T. Vassilev United States	22	2.1k 1.1×	1.4k 0.9×	230 0.5×	328 0.8×	128 0.5×	37	2.8k
Carlos Becerra United States	24	1.4k 0.7×	1.1k 0.6×	398 0.9×	379 0.9×	85 0.3×	98	2.5k

Countries citing papers authored by Brian Higgins

Since Specialization

Citations

This map shows the geographic impact of Brian Higgins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Higgins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Higgins more than expected).

Fields of papers citing papers by Brian Higgins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Higgins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Higgins. The network helps show where Brian Higgins may publish in the future.

Co-authorship network of co-authors of Brian Higgins

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Higgins. A scholar is included among the top collaborators of Brian Higgins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Higgins. Brian Higgins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mascarenhas, John, Francesco Passamonti, Kate Burbury, et al.. (2021). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances. 6(4). 1162–1174. 16 indexed citations

Uy, Geoffrey L., Sarit Assouline, Steven Blotner, et al.. (2020). Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational New Drugs. 38(5). 1430–1441. 16 indexed citations

Konopleva, Marina, Giovanni Martinelli, Naval Daver, et al.. (2020). MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 34(11). 2858–2874. 276 indexed citations breakdown →

Razak, Albiruni R. Abdul, Wilson H. Miller, Geoffrey L. Uy, et al.. (2019). A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors. Investigational New Drugs. 38(4). 1156–1165. 13 indexed citations

Wilson, X., Veerle W. Daniëls, Lisa Ta, et al.. (2017). Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nature Medicine. 23(11). 1342–1351. 84 indexed citations

Zhang, Zhuming, Qingjie Ding, Jinjun Liu, et al.. (2014). Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorganic & Medicinal Chemistry. 22(15). 4001–4009. 42 indexed citations

Higgins, Brian, Kelli Glenn, Antje‐Christine Walz, et al.. (2014). Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach. Clinical Cancer Research. 20(14). 3742–3752. 50 indexed citations

Ding, Qingjie, Zhuming Zhang, Jinjun Liu, et al.. (2013). Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development. Journal of Medicinal Chemistry. 56(14). 5979–5983. 447 indexed citations breakdown →

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2011). Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research. 72(3). 779–789. 170 indexed citations

10.

Wang, Huisheng, Sherif Daouti, Wenhui Li, et al.. (2011). Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation. Cancer Research. 71(16). 5535–5545. 62 indexed citations

11.

He, Wei, Leopoldo Luistro, Daisy Carvajal, et al.. (2011). High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097. Molecular Oncology. 5(3). 292–301. 38 indexed citations

12.

Daouti, Sherif, Brian Higgins, Kenneth Kolinsky, et al.. (2010). Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models. Molecular Cancer Therapeutics. 9(1). 134–144. 23 indexed citations

13.

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research. 70(13). 5518–5527. 307 indexed citations

14.

Daouti, Sherif, Huisheng Wang, Wenhui Li, et al.. (2009). Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research. 69(5). 1924–1932. 25 indexed citations

15.

Tovar, Christian, James Rosinski, Zoran Filipovic, et al.. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proceedings of the National Academy of Sciences. 103(6). 1888–1893. 553 indexed citations breakdown →

16.

McDermott, Lee, Mary Ellen Simcox, Brian Higgins, et al.. (2005). RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: Synthesis and biological evaluation. Bioorganic & Medicinal Chemistry. 13(16). 4835–4841. 17 indexed citations

17.

Simcox, Mary Ellen, Brian Higgins, Lee McDermott, et al.. (2004). 189 Rodent pharmacokinetics and antiangiogenic activity of a pyrimidopyrimidine dual KDR/FGFR antagonist. European Journal of Cancer Supplements. 2(8). 59–59. 3 indexed citations

18.

Melton, Terry, et al.. (2004). Forensic Mitochondrial DNA Analysis of 691 Casework Hairs. Journal of Forensic Sciences. 50(1). JFS2004230–8. 80 indexed citations

19.

Higgins, Brian, Kenneth Kolinsky, Melissa Smith, et al.. (2004). Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anti-Cancer Drugs. 15(5). 503–512. 126 indexed citations

20.

Moinpour, Carol M., Mon Oo Yee, Brent A. Blumenstein, et al.. (1998). Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. JNCI Journal of the National Cancer Institute. 90(20). 1537–1544. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact